Tastemaker Acquisition Corp
Change company Symbol lookup
Select an option...
TMKR Tastemaker Acquisition Corp
SPY SPDR® S&P 500 ETF Trust
STOR STORE Capital Corp
PIPP^ Pine Island Acquisition Corp
PEP PepsiCo Inc
$NASI5000LMN NASDAQ Asia Cnsmr Svcs Large Mid Cap
PNM PNM Resources Inc
CBLAQ CBL & Associates Properties Inc
APLE Apple Hospitality REIT Inc
MET MetLife Inc
Go

Company profile

Tastemaker Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses. The Company has not selected any specific business combination target and may pursue an initial business combination target in any industry or geographic region. The Company is not engaged in any business and has not generated any revenue.

Closing Price
$9.86
Day's Change
-0.01 (-0.10%)
Bid
--
Ask
--
B/A Size
--
Day's High
9.90
Day's Low
9.78
Volume
128,131

UPDATE: Vertex stock falls after protein-deficiency drug development stopped

5:08 pm ET October 14, 2020 (MarketWatch)
Print

Vertex Pharmaceuticals Inc. (VRTX) stock fell in the extended session Wednesday after the biotech company said it would stop developing a drug to treat an inherited protein deficiency that can cause lung and liver disease. Vertex shares fell 9% after hours, following a 1.7% decline to close the regular session at $271.46. The company said it would stop developing VX-814, which was intended to treat alpha-1 antitrypsin deficiency, because of safety issues encountered in a mid-stage clinical trial. "Based on the liver enzyme elevations observed, along with the determination that we would not be able to safely achieve targeted exposure levels with VX-814, we are discontinuing further development of this molecule," said Carmen Bozic, Vertex chief medical officer, in a statement. At Wednesday's close, Vertex shares were up 24% on the year, compared with an 8% gain by the S&P 500 index .

-Wallace Witkowski; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

October 14, 2020 17:08 ET (21:08 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.